Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 572 across all filing types
Latest filing 2023-03-03 Report Publication Anno…
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SoftOx Solutions AS: Invitation to extended fourth quarter presentation
Report Publication Announcement Classification · 95% confidence The document is titled 'SoftOx Solutions AS: Invitation to extended fourth quarter presentation' and explicitly invites recipients to a webcast presentation scheduled for March 8, 2023. It provides registration details and states that the presentation and related materials will be made available online on the same day. This document is an announcement about an upcoming presentation/event, not the presentation itself, nor is it a formal regulatory filing like a 10-K or ER. Since it announces an investor-focused presentation, the most fitting category is Investor Presentation (IP). However, given the short length (1318 chars) and the focus on announcing the *availability* of materials for an event, it strongly aligns with the 'Report Publication Announcement' (RPA) definition, which covers announcements regarding the timing or release of company reports/presentations. Since the document is an invitation to an 'extended fourth quarter presentation', it is announcing an event where materials will be shared. Given the options, RPA is a strong fit for announcing the event/materials release, but IP is also plausible if the event itself is the focus. Since it is an invitation to a presentation, IP (Investor Presentation) is the primary intent, even if the text is just the invitation. Let's re-evaluate against the definitions. It is an invitation to a presentation, which is a type of investor communication. If the actual presentation slides were attached, it would be IP. Since this is just the invitation/announcement of the event, RPA (Report Publication Announcement) is technically correct as it announces the release of materials, but IP (Investor Presentation) captures the subject matter better. Given the context of financial reporting, an announcement about an upcoming investor presentation is often categorized as the presentation itself (IP) if the materials are linked, or RPA if it's just the notice. Since the text states materials *will be made available* at a link, RPA is the most precise fit based on Rule 2 (announcement of publication).
2023-03-03 English
Softox Solutions AS: Q4 2022 Results. Challenging liquidity situation and other company updates
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly report' for Q4 2022, containing detailed financial tables, operational updates, management commentary, and business development highlights. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q4 2022
2023-02-15 English
Softox Solutions AS: Q4 2022 Results. Challenging liquidity situation and other company updates
Earnings Release Classification · 99% confidence The document is titled "Softox Solutions AS: Q4 2022 Results" and provides key highlights for the fourth quarter, including financial results (pre-tax loss), clinical trial updates, regulatory approvals, management changes, and subsequent events related to financing and grants. This content structure strongly indicates a periodic financial results announcement, which aligns with the definition of an Earnings Release (ER). Although it mentions an extended presentation later, the document itself is the initial announcement of the Q4 results, making ER the most appropriate classification over RPA or CT. Q4 2022
2023-02-15 English
SoftOx Solutions AS: Final grant agreement with the European Defence Fund signed
Regulatory Filings Classification · 99% confidence The document is dated January 06, 2022, and is explicitly titled/formatted as a 'PRESS RELEASE' (indicated by 'NRBC risks: the CEA coordinator for the COUNTERACT project', 'PRESS RELEAS', and 'RELEASEPRESS'). It announces the coordination of a European project (COUNTERACT) by the CEA, detailing its goals, funding, and partners. This type of announcement, which communicates company/organizational news to the public and media, fits best under the general category for regulatory or official announcements that are not specific financial reports (like 10-K, ER, or IR). Since it is a formal press release announcing an initiative, and it doesn't fit the specific definitions for financial reports, management changes, or dividend notices, the most appropriate classification is the general regulatory/announcement fallback category, RNS (Regulatory Filings). The document length (5948 chars) is substantial enough that it is the primary content, not just a link to a report, ruling out RPA.
2023-01-09 English
SoftOx Solutions AS: Final grant agreement with the European Defence Fund signed
Capital/Financing Update Classification · 98% confidence The document is a press release from SoftOx Solutions AS announcing the signing of a final grant agreement with the European Defence Fund (EDF) for the COUNTERACT Consortium. This announcement details financing (NOK 97 million funding related to the first phase), project scope (CBRN threats), and strategic implications. This type of announcement, concerning fundraising, financing activities, or significant project funding secured by the company, aligns best with the 'Capital/Financing Update' category. It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). Since it is a specific announcement about securing funding/grants, 'CAP' is the most appropriate classification over the general 'RNS' fallback.
2023-01-09 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for future corporate events like 'Annual Report', 'Annual General Meeting', and various 'Quarterly Reports' for 2023 and 2024. It is not the report itself, nor is it an announcement of a specific report release that has already occurred. It is a forward-looking schedule of corporate events. None of the specific filing types (10-K, ER, IR, AGM-R, etc.) perfectly match a 'Financial Calendar'. However, since it is a formal announcement regarding the timing and schedule of future regulatory/financial disclosures, it best fits the general regulatory announcement category, 'Regulatory Filings' (RNS), as a fallback for scheduling information that doesn't fit the other specific categories.
2022-12-29 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.